RecruitingPhase 3NCT07759154

A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation

A Phase 3b, Multicenter, Open-label, Single-arm Trial to Evaluate the Efficacy and Safety of Orally Administered Centanafadine QD XR Capsules in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.

Enrollment

80 participants

Start Date

Sep 1, 2026

Study Type

INTERVENTIONAL

Conditions

Attention Deficit Hyperactivity Disorder Emotional Dysregulation

Summary

The primary purpose of this study is to evaluate the efficacy of centanafadine once daily (QD) extended-release (XR) capsules in adults with attention-deficit/hyperactivity disorder (ADHD) and emotional dysregulation (ED).

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Centanafadine XR for people with attention deficit hyperactivity disorder and emotional dysregulation. The study is currently recruiting participants at 16 locations. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCentanafadine XR

Oral capsules

Locations(16)

Sarkis Clinical Trials - Gainesville

Gainesville, Florida, United States

CNS Healthcare - Jacksonville (Clinical Neuroscience Solutions - Jacksonville)

Jacksonville, Florida, United States

Accel Research Sites-Maitland

Maitland, Florida, United States

Nola Research Works

New Orleans, Louisiana, United States

Boston Clinical Trials

Boston, Massachusetts, United States

Adams Clinical - Watertown

Watertown, Massachusetts, United States

St. Charles Psychiatric Associates/Midwest Research Group

Saint Charles, Missouri, United States

Center for Psychiatry and Behavioral Medicine. Inc.

Las Vegas, Nevada, United States

Center for Emotional Fitness

Cherry Hill, New Jersey, United States

The Medical Research Network, LLC

New York, New York, United States

Patient Priority Clinical Trials

Cincinnati, Ohio, United States

Summit Research Network

Portland, Oregon, United States

Donald J. Garcia, Jr, MD, PA

Austin, Texas, United States

Houston Clinical Trials LLC

Bellaire, Texas, United States

Kaleidoscope Clinical Research

Houston, Texas, United States

Core Clinical Research

Everett, Washington, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07759154

Related Trials

Developing Brain, Impulsivity and Compulsivity

NCT046310421 location

Washed Microbiota Transplantation for Attention-deficit/Hyperactivity Disorder

NCT063763312 locations

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD

NCT0478114047 locations

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

NCT0427840451 locations

Weighted Blankets for Sleep Disturbance Among Children With ADHD

NCT061941621 location